The utilization of MRD in ALL is evolving rapidly, with certain centers routinely testing for MRD, particularly in the pediatric setting1,2.
MRD has proven to be a key determinant of likely treatment failure or response in ALL1-3. The optimal outcome from the use of novel agents is the production of deep responses, which require sensitive measures to detect. MRD could potentially provide this; allowing the identification of efficacious agents in trials4,5.
- van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015 Jun 25; 125(26): 3996-4009.
- VJHemOnc (2018). Minimal residual disease: a key determinant of ALL treatment response. Available at: https://www.vjhemonc.com/video/3n-t2maeci4-minimal-residual-disease-a-key-determinant-of-all-treatment-response (Accessed: 03 July 2018).
- Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5; 131(14): 1522-1531.
- VJHemOnc (2018). The importance of MRD assessment in all phases of ALL treatment. Available at: https://www.vjhemonc.com/video/8uayqmsw6zu-the-importance-of-mrd-assessment-in-all-phases-of-all-treatment (Accessed: 03 July 2018).
- Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017 Nov 28; 1(25): 2456-2466.